Drug Topics March 1, 2024
Lauren Biscaldi, MS, Managing Editor

Pfizer’s RSV vaccine received FDA approval on May 31, 2023.

Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo remains efficacious in preventing RSV-associated lower respiratory tract disease in adults aged 60 years and older through 2 full RSV seasons, according to topline study data shared by the manufacturer.1

Data were gathered as part of the ongoing phase 3 RENIOR clinical trial (NCT05035212).

“We are encouraged by the level of protection that we observed after 2 full RSV seasons for Abrysvo,” said Annaliesa Anderson, PhD, senior vice president and chief scientific officer, vaccine research and development at Pfizer, in a press release.1 “This new data indicate that broad and durable protection against both types of RSV that cause disease…is the potential benefit...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Healthcare System, Patient / Consumer, Pharma / Biotech, Provider, Public Health / COVID, Survey / Study, Trends
Related Articles:
Pharma Firms Mallinckrodt and Endo Agree to Merge in $6.7B Cash and Stock Deal
FDA Approves First Biosimilar to Omalizumab
Zealand Pharma, Roche Reach Potential $5.3 Billion Deal to Develop Petrelintide for Weight Management
STAT+: Pharmalittle: We’re reading about a Roche deal for an obesity drug, a Gilead HIV drug and more
Roche builds in obesity with $5.3bn Zealand licensing deal

Share This Article